Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Fri, 13 Sep 2024 02:14:00 -0400

STOCKHOLM, Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact.

The North American Phase 3 study is ongoing at 33 study centers in the US and

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Fri, 13 Sep 2024 02:14:00 -0400

The North American Phase 3 study is ongoing at 33 study centers in the US and

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Fri, 13 Sep 2024 02:14:00 -0400

The North American Phase 3 study is ongoing at 33 study centers in the US and

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Fri, 13 Sep 2024 02:14:00 -0400

The North American Phase 3 study is ongoing at 33 study centers in the US and

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Fri, 13 Sep 2024 02:14:00 -0400

The North American Phase 3 study is ongoing at 33 study centers in the US and

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Fri, 13 Sep 2024 02:14:00 -0400

The North American Phase 3 study is ongoing at 33 study centers in the US and

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Fri, 13 Sep 2024 02:14:00 -0400

The North American Phase 3 study is ongoing at 33 study centers in the US and

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Fri, 13 Sep 2024 02:14:00 -0400

The North American Phase 3 study is ongoing at 33 study centers in the US and

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Mon, 24 Jun 2024 11:56:00 -0400

STOCKHOLM, June 24, 2024 /PRNewswire/ -- ("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%. As announced by the Company on June 11^th, 2024, subscription and top guarantee commitments had been made for TO 2, free of charge, with certain external professional investors, and today the board of directors has resolved on a directed issue of 863,333 ordinary shares amounting to approximately SEK

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

Wed, 07 Feb 2024 02:10:00 -0400

STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara^® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

" t is incredibly rewarding to work with such a committed market partner as Allderma", says Anna Ljung, CEO of Moberg Pharma, and continues:" The introduction of Terclara^® to Swedish pharmacy chains

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

Wed, 07 Feb 2024 02:10:00 -0400

STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara^® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

" t is incredibly rewarding to work with such a committed market partner as Allderma", says Anna Ljung, CEO of Moberg Pharma, and continues:" The introduction of Terclara^® to Swedish pharmacy chains

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

Wed, 07 Feb 2024 02:10:00 -0400

STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara^® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

" t is incredibly rewarding to work with such a committed market partner as Allderma", says Anna Ljung, CEO of Moberg Pharma, and continues:" The introduction of Terclara^® to Swedish pharmacy chains

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

Wed, 07 Feb 2024 02:10:00 -0400

STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara^® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

" t is incredibly rewarding to work with such a committed market partner as Allderma", says Anna Ljung, CEO of Moberg Pharma, and continues:" The introduction of Terclara^® to Swedish pharmacy chains

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

Wed, 07 Feb 2024 02:10:00 -0400

STOCKHOLM, Feb. 7, 2024 /PRNewswire/ -- Moberg Pharma ABs (OMX: MOB) marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter (OTC) pharmaceuticals - has now launched sales of MOB-015 under the Terclara^® brand. The interest among pharmacies has been significant for Moberg Pharma's medication against nail fungus.

" t is incredibly rewarding to work with such a committed market partner as Allderma", says Anna Ljung, CEO of Moberg Pharma, and continues:" The introduction of Terclara^® to Swedish pharmacy chains

StreetInsider.com News Articles

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication